scieee Science in your language
[en] (orig)

Development of nevirapine resistance in children exposed to the prevention of mother-to-child HIV-1 transmission programme in Maputo, Mozambique

Abstract

Background: Single-dose nevirapine (sd-NVP) has been the main option for prevention of mother-to-child transmission (PMTCT) of HIV-1 in low-resource settings. However, sd-NVP can induce the selection of HIV-1 resistant mutations in mothers and infants. In Mozambique, there are limited data regarding the profile of NVP resistance associated mutations (RAM) in the context of PMTCT. Objectives: To assess the prevalence and the factors associated with NVP RAM among children born to HIV-1 infected mothers enrolled in the PMTCT programme adopted in Mozambique. Methods: One hundred and fifty seven children aged 6 to 48 weeks were sequentially included (July 2011 to March 2012) at four centres in Maputo. Genotyping of RAM was performed in samples with HIV-1 RNA≥ 100 copies/μL (Viroseq). Sequencing was performed with ABI 3100 (Applied Biosystems). Logistic regression modelling was undertaken to identify the factors associated with NVP RAM. Results: Seventy-nine children had their samples genotyped. Their median age was 7.0 (3–12) months and 92.4% received prophylaxis with sd-NVP at birth plus daily NVP. 35.4% of mothers received antiretrovirals (ARVs) for PMTCT. ARV RAM were detected in 43 (54.4%) of the children. 45.6% of these children had at least one NVP RAM. The most common mutations associated with NVP resistance were K103N (n = 16) and Y181C (n = 15). NVP RAM was significantly associated with mother exposure to PMTCT (crude odds ratio [OR] 30.3, 95% CI 4.93–186.34) and with mother’s CD4 count < 350 cells/mm3 (crude OR 3.08, 95% CI 1.02–9.32). In the multivariable analysis the mother’s exposure to PMTCT was the only variable significantly associated with NVP RAM (adjusted OR 48.65, 95% CI 9.33–253.66). Conclusions: We found a high prevalence of NVP RAM among children who were exposed to the drug regimen for PMTCT in Mozambique. The mothers’ exposure to PMTCT significantly increased the risk of NVP RAM.

Read accessible full text

Development of nevirapine resistance in children exposed to the prevention of mother-to-child HIV-1 transmission programme in Maputo, Mozambique

Author: Antunes, Francisco,Zindoga, Pereira,Gomes, Perpétua,Augusto, Orvalho,Mahumane, Isabel,Veloso, Luís,Valadas, Emília,Camacho, Ricardo
Publisher: PLoS One
Year: 2015
Source: https://repositorio.ulisboa.pt/bitstream/10451/29667/1/Nevirapine_resistance.pdf
RESEARCH ARTICLE
De elopmen o Ne i apine Resis ance in
Child en Exposed o he P e en ion o
Mo he - o-Child HIV-1 T ansmission
P og amme in Mapu o, Mozambique
F ancisco An unes
1
*, Pe ei a Zindoga
2
, Pe pé ua Gomes
3‡
, O alho Augus o
4‡
,
Isabel Mahumane
5‡
, Luís Veloso
6
, Emília Valadas
7
, Rica do Camacho
8‡
1Ins i u o de Saúde Ambien al (ISAMB), Faculdade de Medicina da Uni e sidade de Lisboa, Lisboa,
Po ugal, 2Depa amen o de Medicinas, Ins i u o Nacional de Saúde, Hospi al Cen al de Mapu o, Mapu o,
Mozambique, 3Labo a ó io de Mic obiologia Clínica e Biologia Molecula , Se iço de Pa ologia Clínica,
Cen o Hospi ala Lisboa Ociden al, Lisboa, Po ugal, 4Saúde da Comunidade, Faculdade de Medicina da
Uni e sidade Edua do Mondlane, Mapu o, Mozambique, 5Pla a o mas Tecnológicas, Pla a o ma de
Vi ologia Molecula , Ins i u o Nacional de Saúde, Mapu o, Mozambique, 6Clinical Da a Uni , Eu o ials
Scien i ic Consul an s, Lisboa, Po ugal, 7Clínica Uni e si á ia de Doenças In ecciosas e Pa asi á ias,
Faculdade de Medicina de Lisboa, Lisboa, Po ugal, 8Depa men o Mic obiology and Immunology, Rega
Ins i u e o Medical Resea ch, Leu en, Belgium
‡PG and RC con ibu ed equally o his wok. OA and IM also con ibu ed equally o his wo k.
* an [email protected]
Abs ac
Backg ound
Single-dose ne i apine (sd-NVP) has been he main op ion o p e en ion o mo he - o-child
ansmission (PMTCT) o HIV-1 in low- esou ce se ings. Howe e , sd-NVP can induce he
selec ion o HIV-1 esis an mu a ions in mo he s and in an s. In Mozambique, he e a e lim-
i ed da a ega ding he p o ile o NVP esis ance associa ed mu a ions (RAM) in he con ex
o PMTCT.
Objec i es
To assess he p e alence and he ac o s associa ed wi h NVP RAM among child en bo n
o HIV-1 in ec ed mo he s en olled in he PMTCT p og amme adop ed in Mozambique.
Me hods
One hund ed and i y se en child en aged 6 o 48 weeks we e sequen ially included (July
2011 o Ma ch 2012) a ou cen es in Mapu o. Geno yping o RAM was pe o med in sam-
ples wi h HIV-1 RNA100 copies/μL (Vi oseq). Sequencing was pe o med wi h ABI 3100
(Applied Biosys ems). Logis ic eg ession modelling was unde aken o iden i y he ac o s
associa ed wi h NVP RAM.
PLOS ONE | DOI:10.1371/jou nal.pone.0131994 July 10, 2015 1/12
OPEN ACCESS
Ci a ion: An unes F, Zindoga P, Gomes P, Augus o
O, Mahumane I, Veloso L, e al. (2015) De elopmen
o Ne i apine Resis ance in Child en Exposed o he
P e en ion o Mo he - o-Child HIV-1 T ansmission
P og amme in Mapu o, Mozambique. PLoS ONE 10
(7): e0131994. doi:10.1371/jou nal.pone.0131994
Edi o : So en Gan , Uni e si y o B i ish Columbia,
CANADA
Recei ed: Ma ch 30, 2015
Accep ed: June 9, 2015
Published: July 10, 2015
Copy igh : © 2015 An unes e al. This is an open
access a icle dis ibu ed unde he e ms o he
C ea i e Commons A ibu ion License, which pe mi s
un es ic ed use, dis ibu ion, and ep oduc ion in any
medium, p o ided he o iginal au ho and sou ce a e
c edi ed.
Da a A ailabili y S a emen : All ele an da a a e
wi hin he pape and i s Suppo ing In o ma ion iles.
Funding: This s udy was unded by he Associação
pa a a In es igação e Desen ol imen o da
Faculdade de Medicina (AIDFM). The unde had no
ole in s udy design, da a collec ion and analysis,
decision o publish, o p epa a ion o he manusc ip .
Compe ing In e es s: The co-au ho Luís Veloso is
an employee o Eu o ials, Scien i ic Consul an s.
This company ecei ed hono a ia om he unde o
his p ojec , o suppo in medical w i ing ac i i ies.
Resul s
Se en y-nine child en had hei samples geno yped. Thei median age was 7.0 (3–12)
mon hs and 92.4% ecei ed p ophylaxis wi h sd-NVP a bi h plus daily NVP. 35.4% o
mo he s ecei ed an i e o i als (ARVs) o PMTCT. ARV RAM we e de ec ed in 43 (54.4%)
o he child en. 45.6% o hese child en had a leas one NVP RAM. The mos common
mu a ions associa ed wi h NVP esis ance we e K103N (n = 16) and Y181C (n = 15). NVP
RAM was signi ican ly associa ed wi h mo he exposu e o PMTCT (c ude odds a io [OR]
30.3, 95% CI 4.93–186.34) and wi h mo he ’s CD4 coun <350 cells/mm
3
(c ude OR 3.08,
95% CI 1.02–9.32). In he mul i a iable analysis he mo he ’s exposu e o PMTCT was he
only a iable signi ican ly associa ed wi h NVP RAM (adjus ed OR 48.65, 95% CI 9.33–
253.66).
Conclusions
We ound a high p e alence o NVP RAM among child en who we e exposed o he d ug
egimen o PMTCT in Mozambique. The mo he s’exposu e o PMTCT signi ican ly
inc eased he isk o NVP RAM.
In oduc ion
In 2010, an es ima ed 390 000 child en we e newly in ec ed wi h HIV, p ima ily due o
mo he - o-child ansmission (MTCT) [1]. Ve ical ansmission, which can occu du ing
p egnancy, labou , deli e y o b eas eeding, emains he main mode o HIV in ec ion in chil-
d en [2]. The implemen a ion o p e en i e heal h policies such as p egnancy moni o ing and
he adminis a ion o an i e o i al he apies (ART) led o a ma ked educ ion in MTCT a es
in high-income coun ies [3]. Howe e , in limi ed- esou ce se ings, whe e ull access o ART
has no been achie ed, MTCT a es emain ela i ely high [4].
Two o he s a egic goals o ‘The Global Plan owa ds he elimina ion o new HIV in ec-
ions among child en by 2015 and keeping hei mo he s ali e’a e o achie e an ART co e age
among p egnan women o 90% and o educe MTCT o a es <5%, in low- o medium-
income coun ies wi h high es ima ed p e alence o p egnan women li ing wi h HIV [5]. In
2012, he co e age o ART p og ammes o p e en ion o MTCT (PMTCT) eached 65%
( ange: 57 o 70%), among he sub-Saha an A ican coun ies [4].
Mozambique is one o he nine coun ies in sub-Saha an A ica wi h a p e alence o HIV
in ec ion abo e 10% [6]. In 2009, he co e age o ART in he capi al ci y o Mapu o eached
77%. The PMTCT o HIV is a p io i y o he Mozambican Go e nmen , which has imple-
men ed a na ional scale up plan owa ds he elimina ion o MTCT up o 2015. Howe e , chil-
d en’s access o PMTCT p og ammes in Mozambique is s ill limi ed (~59%) [7].
Single-dose ne i apine (sd-NVP), a non-nucleoside e e se ansc ip ase inhibi o
(NNRTI), was adop ed by se e al A ican coun ies in he PMTCT due o i s good e icacy, low
cos , ease o adminis a ion and long plasma hal -li e [8–10]. Howe e , sd-NVP can induce he
selec ion o HIV-1 esis an mu a ions in mo he s and in an s. A ecen me a-analysis p o ided
a pooled es ima e o NVP esis ance p e alence o 35.7% and 52.6% in women and child en
who used sd-NVP, espec i ely [11]. Some au ho s sugges ha NVP-induced esis ance a e
exposu e o MTCT p ophylac ic p og ammes may limi i ological esponse o subsequen use
o NNRTIs in mo he s and in an s [3,12,13].
Ne i apine Resis ance in MTC HIV-1 T ansmission
PLOS ONE | DOI:10.1371/jou nal.pone.0131994 July 10, 2015 2/12
This does no al e he au ho 's adhe ence o all he
PLOS ONE policies on sha ing da a and ma e ials.
Besides he s anda d medical w i ing ac i i ies, LV
has gi en ele an con ibu ion o he da a analysis
and in e p e a ion, decision-making p ocess, e iew
and inal app o al o he manusc ip . Conside ing ha
LV mee s he au ho ship c i e ia s ipula ed by ICMJE,
all o he au ho s ag ee o include him as co-au ho o
his manusc ip . The o he au ho s ha e decla ed ha
no compe ing in e es s exis .
The p ophylac ic egimen adop ed by Mozambique ollows he Op ion A p econized by he
Wo ld Heal h O ganiza ion (WHO) 2009 Guidelines [14]. In in an s, his op ion consis o sd-
NVP a bi h plus NVP p ophylaxis up o he end o b eas eeding. Mo he s ecei e zido udine
(AZT) an epa um, sd-NVP a he onse o labou and wice daily AZT + lami udine (3TC) o
7 days pos pa um (sd-NVP and AZT + 3TC can be omi ed i AZT an epa um did no exceed
4 weeks). Su eys conduc ed in Mapu o in 2007 and 2009 e ealed a es o ansmi ed d ug
esis ance o all ART classes below 5% [15].
Thus a , he e is limi ed knowledge ega ding he p e alence o NVP i al esis ance mu a-
ions in child en bo n o HIV-1-in ec ed mo he s and who we e exposed o ma e nal o child
p og ams o PMTCT in Mozambique. This knowledge is essen ial o ailo ARV s a egies in
his popula ion and maximize he e ec i eness o ARV egimens in p e en ing MTCT.
In ou wo k, we es ima ed he p e alence o i al esis ance o NVP among child en
exposed o he PMTCT p og amme adop ed in Mozambique. We also explo ed he mos
impo an ac o s associa ed wi h NVP esis ance.
Me hods
Se ing and popula ion
This c oss-sec ional s udy was ca ied ou be ween July 2011 and Ma ch 2012. Child en aged 6
o 48 weeks included in he Mozambican PMTCT p og am and bo n o HIV-1 in ec ed mo h-
e s we e sequen ially en olled in he s udy acco ding o hei scheduled appoin men a ou
paedia ic HIV cen es in Mapu o’s egion. The s udy included mo he s who needed ART o
ea hei own heal h o mo he s who jus needed ARVs o educe he isk o MTCT o HIV.
The PMTCT p o ocol ollowed in Mozambique a he ime o his s udy was based on WHO
Rapid Ad ice—Use o an i e o i al d ugs o ea ing p egnan women and p e en ing HIV
in ec ion in in an s– e sion 2 [14]. HIV-1 in ec ed p egnan women who we e eligible o ART
(p ima ily h ough CD4 sc eening) s a ed his ea men , i espec i e o he ges a ional age,
and con inued h oughou p egnancy, deli e y and he ea e . The i s -line ART egimen
included AZT + 3TC + NVP. The ma e nal ARV p ophylaxis consis ed o an epa um daily
AZT as ea ly as 14 weeks o ges a ion, sd-NVP a onse o labou and wice daily AZT + 3TC
o 7 days pos pa um.
The p ophylaxis in b eas eeding child en consis ed o sd-NVP a bi h and hen daily
adminis a ion o NVP un il one week a e all exposu e o b eas milk ended. Non-b eas eed-
ing child en ecei ed sd-NVP a bi h and hen daily adminis a ion o NVP o AZT un il 4 o
6 weeks o age. HIV-in ec ed in an s ecei ed one o he ollowing ART egimens: AZT o d4T
(s a udine) + 3TC + NVP o AZT o d4T + 3TC + LPV/ (lopina i / i ona i ). Child en wi h-
ou CD4 coun a ailable and ha had ecei ed ART ou o he PMTCT p og amme we e
excluded om he s udy.
W i en in o med consen was ob ained om all child en’s pa en s o legal gua dians.
The s udy was app o ed by Mozambique’s Na ional Heal h Bioe hics Commi ee and by
he Mozambican Minis y o Heal h.
Da a and specimen collec ion
Socio-demog aphic and clinical da a we e ob ained om exis ing medical eco ds. The
mo he - ela ed da a included he WHO clinical s age o disease, ype o PMTCT app oach
(ART o p ophylaxis), p ophylac ic scheme and du a ion o exposu e o ARVs. The mo he ’s
i al load was no assessed a he ime o labou (is no ou ine p ac ice). The child- ela ed a i-
ables we e gende , age, deli e y mode, bi h weigh , eeding p ac ice, CD4 coun , p ophylac ic
egimen and HIV-1 RNA le els.
Ne i apine Resis ance in MTC HIV-1 T ansmission
PLOS ONE | DOI:10.1371/jou nal.pone.0131994 July 10, 2015 3/12
Two samples o pe iphe al blood (5 ml each) we e collec ed om each child by enipunc-
u e. One sample was used o ou ine analysis and he o he was shipped wi hin 5 hou s o he
Immunology Labo a o y o Heal h Na ional Ins i u e in Mozambique. The e, 200 μL we e used
o de e mine he CD4 coun by low cy ome y using FACSCalibu (Bec on-Dickinson, San
Jose, Cali o nia, USA); he emaining sample was cen i uged, plasma was isola ed and s o ed
a -80°C. This sample was shipped o Hospi al Egas Moniz in Lisbon wi hin 12 mon hs a e i s
collec ion, o geno yping o HIV-1 RNA and de ec ion o ARV esis ance associa ed mu a-
ions (RAM). The shipmen was pe o med in leak-p oo con aine s speci ic o ozen samples
and con aining d y ice. Tempe a u e was checked a a i al o labo a o y and no anomalies
we e de ec ed. HIV-1 RNA geno yping was pe o med by means o a comme cially a ailable
ki (Vi oSeq HIV-1 geno yping sys em; Cele a Diagnos ics/Abbo Molecula Diagnos ics,
Rome, I aly) based on RNA ex ac ion, e o ansc ip ion, DNA ampli ica ion, and sequencing
by an au oma ed sequence (ABI 3100; Applied Biosys ems, Fos e Ci y, CA) [16].
Geno yping o ARV RAM was only ca ied ou in samples wi h HIV-1 RNA le els 100
copies/μL, using he S an o d Resis ance Da abase (HIVdb e sion 6.05) [17].
A NVP RAM was conside ed i a leas one o he ollowing gene ic changes in e e se an-
sc ip ase was de ec ed: A98G, K101E, K101H, K101P, K103N, V106A, V106M, V108I, Y181C,
Y181V, Y188L and G190A.
HIV sub ypes we e de e mined by phylogene ic analysis o pol egion sequences, using he
Rega Sub yping Tool 2.0 [18].
S a is ical Analysis
The sample size was calcula ed based on he popula ion o Mapu o, 1.209.993 pe sons, and a
a e o ansmission o HIV d ug esis ance o all ele an ARVs and ARV classes o 4.0%,
obse ed in Malawi [19], a neighbou ing coun y o Mozambique wi h simila cha ac e is ics
(low income, high illi e acy a es, poo sani a ion and high a e o sexual ac i i y). A sample o
120 child en allowed he es ima ion o p e alence o NVP RAM wi h a 95% con idence in e al
(CI) and a ma gin o e o o 3.5%. O e all, 157 child en we e en olled o accoun o specimen
losses abo e 20%.
Quan i a i e a iables we e summa ised as median, minimum and maximum and quali a-
i e a iables we e summa ised as absolu e equency. CIs we e compu ed o he mos p e a-
len mu a ions (>5 cases). Odds a io (OR) and 95%CI we e used o explo e he associa ion
be ween independen a iables and NVP RAM.
The bi a iable analysis was conduc ed o all mo he and child cha ac e is ics po en ially
associa ed wi h NVP RAM. All a iables wi h a p alue 0.20 in he bi a iable analysis, as well
as child’s gende and age, we e included in he mul i a iable logis ic eg ession analysis.
Adjus ed ORs and 95% CIs we e es ima ed o all independen p edic o s in he inal selec ed
logis ic model. All P alues we e wo-sided and he le el o signi icance was se a p<0.05.
S a is ical analysis was pe o med using he S a is ical Package o he Social Sciences, e -
sion 19.0 (SPSS Inc., Chicago, IL, USA).
Resul s
Gene al cha ac e is ics o he eligible popula ion
O e all, 157 child en me he eligibili y c i e ia. The median age o he child en was 7.0 mon hs
(1–12 mon hs) and 90 (57.3%) we e male. Mos child en (75.8%; 119 o 157) had CD4 pe cen -
age >20%. Se en y-one pe cen o mo he s (111 o 157) we e clinical s age 3 o HIV in ec ion
and 127 (80.9%) we e ecei ing ART.
Ne i apine Resis ance in MTC HIV-1 T ansmission
PLOS ONE | DOI:10.1371/jou nal.pone.0131994 July 10, 2015 4/12
Se en y-nine o he 157 child en (50.3%) had hei sample sequenced o geno ypic esis-
ance. The easons o no pe o ming esis ance es s we e he absence o HIV-1 RNA esul s
(n = 22) and unde ec able HIV-1 RNA le els <50 copies/μL (n = 56).
Table 1 summa ises he cha ac e is ics o child en wi h esis ance es esul s as well as he
mo he s’ a iables o in e es . The median age o child en was 7 mon hs (3–12 mon hs) and 49
o 79 (62.0%) we e male. The as majo i y o child en (87.3%; 69 o 79) we e b eas ed and CD4
pe cen age was >20% in 48 o 79 child en (60.8%). ARV p ophylaxis consis ed o sd-NVP a
bi h plus daily NVP in 92.4% o he child en. Almos all he child en had HIV sub ype C, 93.6%
(74 o 79). The emaining sub ypes we e A/C, A/D, C/B, C/D and B (da a no shown).
No s a is ically signi ican di e ences we e ound o any o he a iables o in e es be ween
he 79 child en who had he samples sequenced and he 78 child en who did no .
Table 1. Mo he and child socio-demog aphic and clinical cha ac e is ics among he popula ion wi h
esis ance es esul s.
Child en (n = 79)
Age (mon hs) 7.0 3–12
Male 49 62.0%
Deli e y mode
aginal 66 83.5%
caese ian 13 16.5%
Bi h weigh
2.500 g 43 54.4%
<2.500 g 36 45.6%
Feeding p ac ice
o mula eeding 10 12.7%
exclusi e b eas eeding 69 87.3%
CD4 pe cen age 25.00 2–55%
<10% 10 12.7%
10–20% 21 26.6%
>20% 48 60.8%
ARV p ophylaxis
AZT 6 7.6%
sd-NVP + daily NVP 73 92.4%
Mo he (n = 79)
Clinical s age o HIV in ec ion (WHO)
1 and 2 13 16.5%
3 and 4 66 83.5%
MTCT app oach
†
ART 51 64.6%
P ophylaxis 28 35.4%
Du a ion o exposu e o ARVs (mon hs) 8.00 0–38
CD4 coun (cells/mm
3
) 540.00 108–1120
Da a a e numbe (%), median ( ange).
AZT, zido udine; sd-NVP, single-dose ne i apine; MTCT, mo he - o-child ansmission; ARVs,
an i e o i als; ART, an i e o i al he apy; mm
3
, cubic millili e.
†
The mo he ’sfi s -line ART egimen included AZT + 3TC + NVP. The ma e nal ARV p ophylaxis consis ed
o an epa um daily AZT as ea ly as 14 weeks o ges a ion, sd-NVP a onse o labou and wice daily
AZT + 3TC o 7 days pos pa um.
doi:10.1371/jou nal.pone.0131994. 001
Ne i apine Resis ance in MTC HIV-1 T ansmission
PLOS ONE | DOI:10.1371/jou nal.pone.0131994 July 10, 2015 5/12

The mo he s we e p edominan ly clinical s age 3 o 4 (83.5%; 66 o 79), 28 (35.4%) ecei ed
daily AZT as ea ly a 14 weeks o ges a ion, sd-NVP a onse o labou and wice daily AZT +
3TC o 7 days pos pa um, and 51 (64.6%) we e on i s -line ART egimen. The median du a-
ion o mo he ’s exposu e o ARVs was 8 mon hs (0–38 mon hs) (Table 1).
NVP esis ance associa ed mu a ions (RAM)
ARV RAM we e de ec ed in 43 o he 79 samples ha we e sequenced (54.4%; 95% CI 43.5–
65.4). Thi y-six samples (45.6%; 95% CI 34.6–56.6) had a leas one NNTRI RAM, 33 samples
(41.8%; 95% CI 30.9–52.65) had NRTI RAM and se en samples (8.9%; 95% CI 2.6–15.1) had
PI RAM.
O e all, 74 NNTRI RAM, 54 NRTI RAM and eigh PI RAM we e obse ed. The NNRTI
RAM mos equen ly ep esen ed in his ARV class we e K103N (n = 16, 21.6%, 95% CI 12.2–
31.0) and Y181C (n = 15, 20.3%, 95% CI 11.1–29.4) and G190A (n = 10, 13.5%, 95% CI 5.7–
21.3). M184V (n = 27, 50.0%, 95% CI 36.7–63.3), T69N and D67N (n = 4, 7.4%) we e he mos
common NRTI RAM among his he apeu ic class. PI esis ance mu a ions we e M46I (n = 5,
62.5%) and Q58E (n = 1, 12.5%), L90M (n = 2, 25.0%) (Fig 1).
All he samples wi h NNRTI RAM had a leas one NVP RAM. O e all, 66 NVP RAM we e
ound. O hese, he mos equen mu a ions we e K103N (n = 16, 24.2%, 95% CI 13.4–34.6)
and Y181C (n = 15, 22.7%, 95% CI 12.6–32.8), and G190A (n = 10, 15.2%, 95% CI 6.5–23.8).
The e we e also mul iple occu ences o V108I (n = 6), A98G (n = 6), K101E (n = 4), V106A
(n = 4), K101P (n = 1). The mu a ions K101H, V106M, Y181V and Y188L we e ound in only
one sample each (Fig 2).
Fac o s associa ed wi h geno ypic esis ance o NVP
In he bi a iable analysis, NVP RAM was signi ican ly associa ed wi h mo he ’s exposu e o
p ophylaxis ARV (c ude OR 30.3, 95% CI 4.93–186.34, P<0.0001) and wi h mo he ’s CD4
coun <350 cells/mm
3
(c ude OR 3.08, 95% CI 1.02–9.32, P<0.04). No s a is ically signi ican
associa ion was ound be ween NVP RAM and child- ela ed a iables, mo he HIV clinical
Fig 1. P o ile o d ug esis ance associa ed mu a ions by ARV class. Pe cen ages we e calcula ed based on he o al numbe o RAM ound o each
ARV class (NNTRI = 74, NRTI = 54 and PI = 8).
doi:10.1371/jou nal.pone.0131994.g001
Ne i apine Resis ance in MTC HIV-1 T ansmission
PLOS ONE | DOI:10.1371/jou nal.pone.0131994 July 10, 2015 6/12
s age and du a ion o mo he ’s exposu e o ART (Table 2). In he mul i a iable op imiza ion
logis ic eg ession, he mo he ’s exposu e o p ophylaxis ARV was he only a iable ha
emained signi ican ly associa ed wi h NVP RAM (adjus ed OR 48.65, 95% CI 9.33–253.66,
P<0.001). See S1 Table. S udy Da ase .
Discussion
Ou s udy aimed o es ima e he p e alence o NVP RAM in child en bo n o HIV-1 in ec ed
mo he s and who we e exposed o he PMTCT p og amme p econized in Mozambique. The
p e alence o NVP RAM ound in ou sample was app oxima ely 46%. This a e is wi hin he
b oad ange o p e alence a es o NVP RAM ound among se e al sub-Saha an A ican coun-
ies, which a ies om 27%, in Sou h A ica, o 76% in Malawi [20–22]. In 2010, a p ospec i e
s udy wi h 740 Mozambican child en who had ecei ed sd-NVP p ophylaxis e ealed a high
a e o NVP esis ance (87%) among he g oup wi h es ablished in u e o in ec ion and a a e o
38% when in ec ion occu ed in he pe ipa um pe iod [23].
O no ice, almos all o he child en had sub ype C HIV in ec ion. This inding is in line
wi h a es p e iously obse ed in Mozambique. Se e al s udies showed ha bo h women and
in an s wi h sub ype C HIV a e mo e likely o de elop NVP esis ance a e exposu e o sd-
NVP han hose in ec ed wi h o he HIV sub ypes [24,25].
We ound ha he mo he s who ook AZT and/o sd-NVP o p o ide MTCT p ophylaxis
o hei in an , ins ead o combina ion ART and wi h a low CD4 coun had a s a is ically signi -
ican associa ion wi h NVP RAM in he bi a iable analysis. Child en whose mo he s had CD4
coun <350 cells/mm
3
, had a highe isk o NVP esis ance han hose child en whose mo he s
Fig 2. P o ile o NVP esis ance associa ed mu a ions (RAM). Pe cen ages we e calcula ed based on he o al numbe o NVP RAM (n = 66). K103N and
Y181C we e he mos equen NVP RAM (24.2% and 22.7% o he samples, espec i ely).
doi:10.1371/jou nal.pone.0131994.g002
Ne i apine Resis ance in MTC HIV-1 T ansmission
PLOS ONE | DOI:10.1371/jou nal.pone.0131994 July 10, 2015 7/12
had CD4 coun 350 cells/mm
3
(OR = 3.08). The low CD4 coun obse ed in mo he s could
be a ibu able o i ological ailu e and selec ion o esis ance, which, in u n, could be ans-
mi ed o he child. The majo i y o mo he s in ou sample (84%) we e clinical s age 3 o 4 o
HIV in ec ion.
In he mul i a iable logis ic model he mo he s ha ook an i e o i als o p ophylaxis hei
e us/in an signi ican ly inc eased isk o NVP esis ance (OR = 48.65) among child en
Table 2. Logis ic eg ession p edic ing NVP RAM adjus ed o independen a iables o in e es .
NVP RAM
(n = 36)
Wi hou NVP
RAM (n = 43)
C ude OR (95%
CI)
P- alue Adjus ed OR (95%
CI)*
P-
alue
Child gende
Female 12 40.0% 18 60.0% e e ence
Male 24 48.0% 25 51.0% 1.44 (0.57–3.65) 0.4396 0.88 (0.25–3.12) 0.853
Child age (mon hs)
<6 9 36.0% 16 64.0% e e ence
6–12 27 50.0% 27 50.0% 1.78 (0.66–4.79) 0.2482 1.85 (0.50–6.87) 0.356
mean age ±SD 7.80 ±2.89 6.67 ±2.58 0.061
Deli e y mode
Vaginal 7 53.9% 6 46.2% e e ence
Caese ian 29 43.9% 37 56.1% 0.67 (0.20–2.24) 0.5148
Bi h weigh (g)
<2500 18 50.0% 18 50.0% 1.39 (0.57–3.42) 0.4690
2500 18 41.9% 25 58.1% e e ence
Feeding p ac ice
Exclusi e b eas eeding 33 47.8% 36 52.2% e e ence
In an o mula 3 30.0% 7 70.0% 0.47 (0.11–2.00) 0.2932
P ophylaxis wi h NVP in child en 32 45.7% 40 57.1% 0.60 (0.12–2.92) 0.5222
Mo he exposu e o ARV
ART 11 21.6% 40 78.4% e e ence
MTCT P ophylaxis 25 89.3% 3 10.7% 30.3 (4.93–
186.34)
<0.0001 48.65 (9.33–253.66) <0.001
Mo he CD4 coun (cells/mm
3
)
<350 12 66.7% 6 33.3% 3.08 (1.02–9.32) 0.0408 1.75 (0.37–8.26) 0.477
350 24 39.3% 37 60.7% e e ence
mean CD4 coun 504.44 ±283.14 619.23 ±214.18 0.043
Du a ion o mo he ’s exposu e o ARVs
(mon hs)
0.31 (0.08–1.31) 0.111
<12 8 33.3% 16 66.7% e e ence
12 28 50.9% 27 49.1% 2.07 (0.75–5.75) 0.1517
Mo he WHO s aging o HIV in ec ion
1 and 2 6 46.2% 7 53.9% e e ence
3 and 4 30 45.5% 36 54.6% 0.97 (0.29–3.23) 0.9633
Da a a e numbe (%); mean (s anda d de ia ion).
*The ollowing independen a iables we e included in he mul iple logis ic adjus ed eg ession analysis: child gende , child age, mo he exposu e o
ARV, mo he CD4 coun , ma e nal du a ion o exposu e o ARVs.
Values in bold deno e s a is ical significance.
ART, an i e o i al he apy; CI, Confidence In e al; OR, Odds Ra io; NVP RAM, ne i apine esis ance associa ed mu a ions; MTCT, mo he - o-child-
ansmission; mm
3
, cubic millili e.
doi:10.1371/jou nal.pone.0131994. 002
Ne i apine Resis ance in MTC HIV-1 T ansmission
PLOS ONE | DOI:10.1371/jou nal.pone.0131994 July 10, 2015 8/12
compa ing o mo he s who ecei ed ART. This inding co obo a es he esul s obse ed in
Mapu o by Vaz e al [26], subs an ia ing he e idence ha sd-NVP-based p ophylac ic egi-
mens lead o a ma ked inc ease in he isk o esis ance o his ARV and o he subsequen use
o NNRTIs [3,12,27,28].
In ou s udy, he isk o i al esis ance o NVP was nume ically highe among child en
whose mo he s we e exposed o ARVs o mo e han 12 mon hs bu his inding had no s a is-
ical signi icance (OR = 2.07).
In ou sample, a high p opo ion o child en (87.3%) we e b eas ed. An analysis o b eas
milk samples om mo he s o ci y o Bei a in Mozambique who we e exposed o sd-NVP,
showed a pe sis ence o NVP- esis an HIV-1 up o 8 mon hs pos pa um [29]. A ound 48% o
he child en in ou s udy ha we e b eas ed had NVP esis ance, which is abo e he a e o
NVP esis ance de ec ed in Bei a, Mozambique (37.5%) [30] and below he a e ound in
Malawi (66%) [21]. In he bi a iable analysis we ound no s a is ically signi ican associa ion
be ween b eas eeding and an inc eased isk o NVP RAM.
Thi y-six o he 79 child en ha we e success ully geno yped in ou s udy exhibi ed a leas
one mu a ion con e ing esis ance o NNRTIs. The mos equen e e se ansc ip ase mu a-
ions we e Y181C, K103N and G190A. Simila esis ance pa e ns ha e been ound in o he
s udies [31–33]. PI RAM we e de ec ed in a small sample o child en, which e lec s he low use
o PI in his popula ion.
Limi a ions
The ac ha we did no know he mo he s ART his o y and hei ARV esis ance p o ile con-
s i u es one majo limi a ion o ou s udy. As a esul , we could no disc imina e be ween esis-
ance mu a ions ha we e due o ART o PMTCT and he ones ha we e selec ed in he child.
WHO endo ses he egula su eillance o ARV esis an HIV in pa ien s who ecei e ART o
he i s ime. Se e al s udies conduc ed in sub-Saha an A ican coun ies ound a es o p i-
ma y esis ance a ound 5% [34]. Fu he mo e, we we e unable o iden i y i mo he s we e p e-
iously exposed o NVP-con aining egimens and, he e o e, assess he impac o his po en ial
con ounde o NVP esis ance de elopmen .
We ha e no in es iga ed he pe sis ence o de ec able NVP esis ance in ou sample. E i-
dence shows ha child en’s exposu e o sd-NVP is associa ed wi h NVP- esis an mu a ions
ha can pe sis o a yea o mo e [35–37]. This pe sis ence seems o be mo e ma ked a e
exposu e o ex ended NVP p ophylaxis [38,39]. Among HIV-in ec ed Ugandan in an s wi h
NVP esis ance a 6 weeks o age, NVP- esis an HIV a ian s we e s ill de ec ed a 6 mon hs
in all se en in an s who ecei ed he ex ended NVP egimen, compa ed o only one o six
in an s who ecei ed sd-NVP alone [38].
A la ge sample would ha e p o ided mo e obus indings ega ding he ou comes o in e -
es . Some o he specimens we e no sequenced due o poo quali y o delay in i s shipmen .
Mo eo e , he a ailable sequencing assays we e no able o de ec esis ance o samples wi h
HIV RNA le els <100 copies/μL.
Wi h he apid scale up o ART in Mozambique, mo e han 16.000 child en ha e been
exposed o ARVs up o 2011. Despi e g adually imp o ing access o ART, he p opo ion o
child en cu en ly ea ed in he coun y is conside ably small. As o Decembe 2010 only 23%
o HIV-in ec ed child en aged <15 yea s old in need o ART we e ecei ing his he apy [26,
33].
The iden i ica ion o he ac o s mos associa ed wi h i ological esponse and p e en ion o
esis ance o ARVs is c ucial o an app op ia e managemen o ART p og ammes, he op imi-
za ion o he use o esou ces and a be e de ini ion o ea men s a egies. This knowledge is
Ne i apine Resis ance in MTC HIV-1 T ansmission
PLOS ONE | DOI:10.1371/jou nal.pone.0131994 July 10, 2015 9/12